SHH · 603259.SS
WuXi AppTec Co., Ltd.
CN¥142.89-CN¥0.00 (0.0%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.69% below the high.
Loading market information…
SHH · 600062.SS · CNY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 05:57 AM UTC. Cached market data; not a live quote.
One-year closing-price history · CNY. Historical prices are not a forecast.
China Resources Double-Crane Pharmaceutical Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.9% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
China Resources Double-Crane Pharmaceutical Co.,Ltd.’s forward annual dividend is CN¥0.76 per share, paid semi-annual. The forward yield is 4.91% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
China Resources Double-Crane Pharmaceutical Co.,Ltd.’s next earnings report is currently expected on Mar 19, 2027. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow China Resources Double-Crane Pharmaceutical Co.,Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.
Latest available per-share figures in CNY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:12 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q1 2025 |
|---|
| Apr 26, 2025 |
| CN¥0.49 |
| CN¥3.08B |
| Q4 2024 | Mar 19, 2025 | CN¥0.22 | CN¥2.66B |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
CN¥142.89-CN¥0.00 (0.0%)
WuXi AppTec Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 17.69% below the high.
CN¥48.75+CN¥0.13 (+0.27%)
Jiangsu Hengrui Medicine Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 25.95% below the high.
HK$51.00+HK$0.35 (+0.69%)
Jiangsu Hengrui Pharmaceuticals Co.,Ltd’s quoted price sits in the lower half of its reported 52-week range, 37.0% below the high.
CN¥182.97+CN¥3.97 (+2.22%)
Shenzhen Mindray Bio-Medical Electronics Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 18.5% below the high.
HK$32.54-HK$0.54 (-1.63%)
Hansoh Pharmaceutical Group Company Limited’s quoted price sits in the lower half of its reported 52-week range, 26.41% below the high.
CN¥40.27-CN¥1.03 (-2.49%)
Sichuan Kelun Pharmaceutical Co., Ltd. Class A’s quoted price sits in the lower half of its reported 52-week range, 23.7% below the high.
CN¥11.83+CN¥0.04 (+0.34%)
Beijing Aosaikang Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 41.32% below the high.
CN¥7.80+CN¥0.15 (+1.96%)
Beijing Science Sun Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 43.48% below the high.
